What are the best biotech newsletters to follow?

For biotech professionals and curious minds alike, a handful of newsletters consistently rise above the noise: STAT News, BioPharma Dive, and The Readout from Endpoints News are widely regarded as the gold standard trio for daily biotech intelligence. Each brings a distinct editorial lens — STAT for investigative depth, BioPharma Dive for deal and regulatory tracking, and Endpoints for the raw, fast-moving pulse of drug development and industry gossip that insiders actually talk about.

What makes these outlets particularly valuable right now is the sheer velocity of the sector. The FDA has been operating at a brisk approval pace in 2025, with GLP-1 therapies, ADC (antibody-drug conjugate) platforms, and cell and gene therapy pipelines dominating coverage. STAT News has been especially sharp in its reporting on the political pressures reshaping the FDA under new leadership, while Endpoints News broke down the implications of several high-profile clinical trial readouts this week across oncology and rare disease. BioPharma Dive, meanwhile, has kept meticulous score on the M&A wave — a critical thread as large pharma companies like AstraZeneca and Eli Lilly continue hunting for pipeline assets to offset looming patent cliffs.

Beyond the big three, Nature Biotechnology's weekly digest is essential for those who want peer-reviewed signal alongside market noise. For a more curated, analytical take, Timmerman Report offers long-form perspective from veteran journalist Luke Timmerman, particularly strong on emerging platforms like RNA medicine and synthetic biology. If you're tracking the venture and startup layer, Rock Health's newsletter and Fierce Biotech round out a comprehensive reading stack without overwhelming your inbox.

The next frontier to watch closely is how AI-drug discovery companies — Recursion Pharmaceuticals, Isomorphic Labs, and others — translate their computational promises into actual clinical data. The newsletters listed above will be your early warning system when those readouts land, and they're increasingly dedicating editorial real estate to separating genuine platform breakthroughs from well-funded hype. Bookmark them, set up alerts, and treat your reading list as a living portfolio.

— Pulse